drugset / Trial / NCT05288166
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
Timeline
- Start
- 2022-04-14
- Primary completion
- 2024-02-15
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 200 mg | Oral |
| Background | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Background | Prednisolone | Other / unclassified | 5 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |